Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.Peer-Reviewed Original ResearchConceptsCase seriesAdvanced imagingTreatment planningCommon primary brain tumorNon-contrast enhancementPostcontrast MRI scansStandard care pathwayRecent clinical studiesPrimary brain tumorsContrast enhancementMagnetic resonance imaging (MRI) measurementsTumor Treating FieldsStandard treatment planningPrior therapyDisease activityNonmeasurable diseaseStandard therapySurvival benefitTumor burdenPoor prognosisTumor locationCare pathwayClinical evaluationClinical trialsPatient outcomesACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI
Blondin N. ACTR-08. BENEFICIAL EFFECT OF TUMOR TREATING FIELD THERAPY IN DIFFUSE ASTROCYTOMA WITH GLIOMATOSIS CEREBRI. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.007.Peer-Reviewed Original ResearchSignificant radiographic improvementGliomatosis cerebriRadiographic improvementDiagnostic biopsyCerebral lobesRadiation therapyDiffuse astrocytomasTTFields therapyCombination of TTFieldsCycles of TMZYear old manYear old womanEffective treatment strategiesTumor treating fields therapyTumor Treating FieldsActive diseasePerformance statusRadiographic progressionSurvival benefitAdult astrocytomasNeurological toxicityPatient 1Patient 2Poor prognosisMalignant disease